SEC Filings

8-K
PERNIX THERAPEUTICS HOLDINGS, INC. filed this Form 8-K on 02/19/2019
Entire Document
 

 

14 Net Sales Forecast $24 $28 $28 $29 $31 $34 $23 $23 $21 $10 $5 $6 $68 $31 $10 $10 $10 $10 $31 $9 $9 $9 $8 $8 $0 $20 $40 $60 $80 $100 $120 $140 $160 2017A 2018E 2019E 2020E 2021E 2022E Zohydro Silenor Treximet Brand and Authorized Generic Generics / Other Forecast • Compression in 2018E Treximet ® franchise revenue driven by ( i ) loss of exclusivity in February 2018, which enabled three competitors to enter the market and (ii) lower than anticipated gross - to - nets on branded Treximet ® due to delayed MAC pricing from managed care providers and low net pricing for Treximet ® AG as a result of pricing pressure from generic entrants • Withdrawal of IDA (1) and desvenalfaxine ($18.2M 2017A revenue) contributed to lower 2018E revenue for Generics / Other • Silenor LOE to occur in January 2020; opportunity to complete an OTC switch through a development partner Notes: Projections are subject to numerous assumptions and risks. For Zohydro ® ER, assumes settlement with IP litigation counterparties. (1) Isometheptene /Dichloralphenazone/APAP Capsules. $146 $91 $68 $57 $55 $57 ($ in millions) A B C A B C